We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

236 hedge funds and large institutions have $3.87B invested in Ultragenyx Pharmaceutical in 2023 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 94 increasing their positions, 75 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 23

54% more capital invested

Capital invested by funds: $2.52B → $3.87B (+$1.36B)

25% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 75

8% more funds holding

Funds holding: 219 → 236 (+17)

0.1% less ownership

Funds ownership: 98.74% → 98.64% (-0.1%)

1% less call options, than puts

Call options by funds: $23.1M | Put options by funds: $23.4M

40% less funds holding in top 10

Funds holding in top 10: 5 → 3 (-2)

Holders
236
Holders Change
+17
Holders Change %
+7.76%
% of All Funds
3.44%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.04%
New
44
Increased
94
Reduced
75
Closed
23
Calls
$23.1M
Puts
$23.4M
Net Calls
-$285K
Net Calls Change
-$1.62M

Top Buyers

1
Sands Capital Management
Sands Capital Management
Virginia
+$59.7M
2
RI
RTW Investments
New York
+$57.5M
3
SCM
Suvretta Capital Management
New York
+$56.1M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$55.8M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$36.2M

Top Sellers

1
ACA
Avoro Capital Advisors
New York
-$44.6M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$30.3M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$23.8M
4
FLAM
First Light Asset Management
Minnesota
-$14.7M
5
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$9.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
Rafferty Asset Management
51
Rafferty Asset Management
New York
$10.6M +$1.51M +38,859 +21%
TD Asset Management
52
TD Asset Management
Ontario, Canada
$10.6M +$620K +16,000 +8%
CS
53
Credit Suisse
Switzerland
$10.4M -$1.19M -30,741 -12%
Franklin Resources
54
Franklin Resources
California
$10.3M +$975K +25,144 +13%
SFM
55
Sphera Funds Management
Israel
$9.61M -$2.25M -58,091 -22%
Russell Investments Group
56
Russell Investments Group
United Kingdom
$9.59M +$648K +16,728 +9%
Citadel Advisors
57
Citadel Advisors
Florida
$9.57M +$7.7M +198,653 +14,179%
Two Sigma Advisers
58
Two Sigma Advisers
New York
$9.03M -$1.57M -40,600 -18%
MCM
59
Moore Capital Management
New York
$8.85M +$1.36M +35,000 +23%
AQR Capital Management
60
AQR Capital Management
Connecticut
$8.16M +$6.62M +170,689 New
VOYA Investment Management
61
VOYA Investment Management
Georgia
$8.07M +$3.62M +93,286 +124%
PFM
62
Privium Fund Management
Netherlands
$8.02M +$1.99M +51,265 +44%
Barclays
63
Barclays
United Kingdom
$7.97M +$1.79M +46,049 +38%
MFWM
64
Motley Fool Wealth Management
Virginia
$7.86M -$156K -4,024 -2%
BNP Paribas Financial Markets
65
BNP Paribas Financial Markets
France
$7.52M -$2.21M -56,994 -27%
Goldman Sachs
66
Goldman Sachs
New York
$7.41M -$9.16M -236,251 -60%
Walleye Capital
67
Walleye Capital
New York
$7.26M -$3.03M -78,278 -34%
MFAM
68
Motley Fool Asset Management
Virginia
$7.15M -$258K -6,661 -4%
CS
69
Candriam SCA
Luxembourg
$7.1M +$3.84M +99,000 +200%
Assenagon Asset Management
70
Assenagon Asset Management
Luxembourg
$6.82M -$2.65M -68,380 -32%
Swiss National Bank
71
Swiss National Bank
Switzerland
$6.77M -$547K -14,100 -9%
Aberdeen Group
72
Aberdeen Group
United Kingdom
$6.75M +$5.47M +141,117 New
Two Sigma Investments
73
Two Sigma Investments
New York
$6.05M +$3.39M +87,410 +223%
WCM Investment Management
74
WCM Investment Management
California
$5.84M +$512K +13,220 +12%
Jane Street
75
Jane Street
New York
$5.77M +$3.53M +91,065 +307%
1 2
3
4 5

RARE Hedge Fund Activity: Q4 2023 in Review

236 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2023, worth a combined $3.87B — up 54% from $2.52B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new RARE positions and 23 closed out — a net gain of 21 holders — while 94 added to existing stakes and 75 trimmed.

The largest buyer was Sands Capital Management, adding an estimated $59.7M. The largest seller was Avoro Capital Advisors, cutting an estimated $44.6M.

  • 236 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2023, up from 219 in Q3 2023.
  • Funds reported $3.87B of Ultragenyx Pharmaceutical stock for Q4 2023, up 54% quarter-over-quarter.
  • 44 funds opened new Ultragenyx Pharmaceutical positions in Q4 2023 and 23 closed out, a net change of +21 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q4 2023 was Sands Capital Management, an estimated $59.7M added.
  • The largest Ultragenyx Pharmaceutical seller in Q4 2023 was Avoro Capital Advisors, an estimated $44.6M sold.

Based on aggregated 13F filings for Q4 2023.